- Record: found
- Abstract: found
- Article: not found
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Carsten Bokemeyer
1 ,
Igor Bondarenko ,
Anatoly Makhson ,
Joerg T Hartmann ,
Jorge Aparicio ,
Filippo de Braud ,
Serban Donea ,
Heinz Ludwig ,
Gunter Schuch ,
Christopher Stroh ,
Anja H Loos ,
Angela Zubel ,
Piotr Koralewski
Feb 10 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation status was investigated.